Abstracts tagged "SLE and auto-immunity"

Abstract Number: 2648 • 2017 ACR/ARHP Annual Meeting
The SLE Risk Variant, Reference Single Nucleotide Polymorphism (rs)10499197, Upstream of Tumor Necrosis Factor Alpha-Induced Protein 3 (TNFAIP3) Modulates Enhancer Function and TNFAIP3 Gene Expression
Ajay Nair¹, Satish Pasula², Yao Fu³ and Patrick Gaffney⁴, ¹Arthritis and Clinical immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, oklahoma city, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Genome Wide Association studies (GWAS) have identified several variants in the tumor necrosis factor alpha-induced protein 3 (TNFAIP3) gene associated with autoimmune disease. TNFAIP3…
Abstract Number: 1951 • 2014 ACR/ARHP Annual Meeting
A Novel CD27^(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE
Sarah Fleischer¹, Claudia Giesecke¹, Henrik Mei¹, Peter E. Lipsky², Capucine Daridon³ and Thomas Dörner³, ¹Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), Berlin, Germany, Berlin, Germany, ²Peking Union Medical College Hospital, Beijing, China, ³CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease known to be associated with a breakdown of self-tolerance, B-cell hyperactivity and disturbed B-cell homeostasis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].